Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical characteristics of patients infected with the 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
Academic google
Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, Consortium C-GU, et al. SARS-CoV-2 variant biology: immune escape, transmission, and fitness. Nat Rev Microbiol. 2023; 21:162–77.
Academic google
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl J Med. 2020;383:2603–15.
Academic google
Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–92.
Academic google
Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for the prevention of Covid-1 N. Engl J Med. 2022;386:2188–200.
Academic google
Kertes J, Shapiro Ben David S, Engel-Zohar N, Rosen K, Hemo B, Kantor A, et al. Association between AZD7442 (Tixagevimab-Cilgavimab) administration and severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection, hospitalization, and mortality. Clin Infect Dis. 2023;76:e126–32.
Academic google
Jondreville L, D’Aveni M, Labussiere-Wallet H, Le Bourgeois A, Villate A, Berceanu A, et al. Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in allogeneic hematopoietic stem cell transplant recipients during the wave of Omicron: a multicenter retrospective study of SFGM-CT. J Hematol Oncol. 2022;15:169.
Academic google
Davis JA, Granger K, Roubal K, Smith D, Gaffney KJ, McGann M, et al. Efficacy of tixagevimab-cilgavimab in the prevention of SARS-CoV-2 in patients with B-cell malignancies. Blood. 2023; 141:200–3.
Academic google
Nguyen Y, Flahault A, Chavarot N, Melenotte C, Cheminant M, Deschamps P, et al. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients. Clin Microbiol Infect. 2022;28:1654.e1651–54.
Academic google
Ministry of Health, Labor and Welfare, Japan. The number of confirmed daily COVID-19 in Japan. (in Japanese) https://www.mhlw.go.jp/stf/covid-19/open-data.htmlaccessed March 2023.
Yamasoba D, Kosugi Y, Kimura I, Fujita S, Uriu K, Ito J, et al. Neutralization sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies. Lancet Infect Dis. 2022;22:942–3.
Academic google
Takashita E, Yamayoshi S, Simon V, van Bakel H, Sordillo EM, Pekosz A, et al. Efficacy of antibodies and antiviral drugs against Omicron subvariants BA.2.12.1, BA.4 and BA.5. N. Engl J Med. 2022;387:468–70.
Academic google
Ministry of Health, Labor and Welfare, Japan. Variants of surveillance results. (in Japanese) https://www.mhlw.go.jp/content/10900000/001076914.pdfaccessed March 2023.
Loo YM, McTamney PM, Arends RH, Abram ME, Aksyuk AA, Diallo S, et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has a long half-life in humans. Sci Transl Med. 2022;14:eabl8124.
Academic google